Jeff Yass’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-163,600
| Closed | -$6.58M | – | 13334 |
|
|
2026
Q1 | $6.58M | Buy |
163,600
+52,800
| +48% | +$1.14M | ﹤0.01% | 3777 |
|
|
2025
Q4 | $2.78M | Buy |
110,800
+35,100
| +46% | +$824K | ﹤0.01% | 5005 |
|
|
2025
Q3 | $1.71M | Sell |
75,700
-90,200
| -54% | -$2.1M | ﹤0.01% | 6122 |
|
|
2025
Q2 | $2.87M | Sell |
165,900
-3,700
| -2% | -$68.5K | ﹤0.01% | 5043 |
|
|
2025
Q1 | $3.71M | Buy |
169,600
+17,000
| +11% | +$470K | ﹤0.01% | 4228 |
|
|
2024
Q4 | $4.87M | Sell |
152,600
-60,200
| -28% | -$1.81M | ﹤0.01% | 3636 |
|
|
2024
Q3 | $6.14M | Sell |
212,800
-62,100
| -23% | -$2.3M | ﹤0.01% | 3271 |
|
|
2024
Q2 | $10.5M | Sell |
274,900
-56,200
| -17% | -$2.55M | ﹤0.01% | 2426 |
|
|
2024
Q1 | $19.5M | Sell |
331,100
-56,100
| -14% | -$3.58M | ﹤0.01% | 1805 |
|
|
2023
Q4 | $23.2M | Sell |
387,200
-8,500
| -2% | -$431K | ﹤0.01% | 1651 |
|
|
2023
Q3 | $15.1M | Buy |
395,700
+166,900
| +73% | +$7.33M | ﹤0.01% | 2070 |
|
|
2023
Q2 | $20.8M | Sell |
228,800
-107,600
| -32% | -$9.28M | ﹤0.01% | 1681 |
|
|
2023
Q1 | $22.2M | Buy |
336,400
+117,400
| +54% | +$6.77M | ﹤0.01% | 1607 |
|
|
2022
Q4 | $11.3M | Buy |
219,000
+66,500
| +44% | +$3.53M | ﹤0.01% | 2119 |
|
|
2022
Q3 | $10.4M | Buy |
152,500
+81,000
| +113% | +$4.79M | ﹤0.01% | 2099 |
|
|
2022
Q2 | $3.23M | Sell |
71,500
-65,400
| -48% | -$2.98M | ﹤0.01% | 3927 |
|
|
2022
Q1 | $6.96M | Buy |
136,900
+83,200
| +155% | +$3.67M | ﹤0.01% | 3096 |
|
|
2021
Q4 | $2.54M | Sell |
53,700
-697,400
| -93% | -$27.5M | ﹤0.01% | 4967 |
|
|
2021
Q3 | $24.8M | Buy |
751,100
+257,100
| +52% | +$14.4M | ﹤0.01% | 1757 |
|
|
2021
Q2 | $31.2M | Buy |
494,000
+403,100
| +443% | +$20.8M | ﹤0.01% | 1567 |
|
|
2021
Q1 | $3.9M | Buy |
90,900
+32,500
| +56% | +$1.54M | ﹤0.01% | 4401 |
|
|
2020
Q4 | $3.34M | Buy |
58,400
+17,400
| +42% | +$736K | ﹤0.01% | 4129 |
|
|
2020
Q3 | $1.24M | Sell |
41,000
-66,100
| -62% | -$1.97M | ﹤0.01% | 5611 |
|
|
2020
Q2 | $3.5M | Sell |
107,100
-33,300
| -24% | -$1.07M | ﹤0.01% | 3541 |
|
|
2020
Q1 | $3.76M | Buy |
140,400
+15,100
| +12% | +$536K | ﹤0.01% | 2950 |
|
|
2019
Q4 | $3.84M | Buy |
125,300
+108,100
| +628% | +$2.99M | ﹤0.01% | 3348 |
|
|
2019
Q3 | $414K | Buy |
+17,200
| New | +$473K | ﹤0.01% | 7682 |
|
Other funds holding APLS
Jeff Yass's APLS Position: Q2 2026 in Review
Jeff Yass sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 340,086 shares — an estimated $13.7M sold.
Jeff Yass first reported a position in APLS in Q2 2019 and held it in 28 quarters. The position peaked at $28.8M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Jeff Yass reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 340,086 Apellis Pharmaceuticals shares in Q2 2026, an estimated $13.7M.
- Jeff Yass first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 28 quarters.
- Jeff Yass's Apellis Pharmaceuticals position peaked at $28.8M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.